RespiVert Report issue

For profit Phase 1 Phase 2
Founded: High Wycombe United Kingdom (2006)
Status: Acquired by Centocor (2010) → now Johnson and Johnson (1999)

Organization Overview

First Clinical Trial
2010
NCT01230645
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Respivert Ltd